- Coordinator
- Universitaet Fuer Bodenkultur Wien, Austria
- Runs
- 1 February 2024 to 31 January 2028
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 23 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101119562
What the project is doing
In the project's own words, from its summary on CORDIS.
Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research and industry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requires not only pushing back the frontiers of instrumentation, fundamental understanding and applications – but harmonisation is essential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types, laboratories and research areas need to be scrutinised and overcome.
The MobiliTraIN Doctoral Network will form 13 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity.
Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 10 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitaet Fuer Bodenkultur Wien | Wien | Austria | Coordinator |
| Janssen Pharmaceutica NV | Beerse | Belgium | Associatedpartner |
| Quality Assistance | Donstiennes | Belgium | Associatedpartner |
| Universiteit Antwerpen | Antwerpen | Belgium | Participant |
| Accelopment Schweiz AG | Zurich | Switzerland | Associatedpartner |
| Universite De Geneve | Geneve | Switzerland | Associatedpartner |
| envibee GmbH | Dübendorf | Switzerland | Associatedpartner |
| Analytisches Forschungsinstitut für Non-Target Screening GmbH (AFIN-TS) | Wallerstein | Germany | Associatedpartner |
| Bruker Daltonics GmbH & Co Kg | Bremen | Germany | Participant |
| Bundesanstalt Fuer Materialforschung Und -Pruefung | Berlin | Germany | Associatedpartner |
| Freie Universitaet Berlin | Berlin | Germany | Participant |
| Gilles Toussaint | Germany | Associatedpartner | |
| Universitatsklinikum Jena | Jena | Germany | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Ecole Nationale Veterinaire, Agroalimentaire Et De L'alimentation Nantes Atlantique | Nantes | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universite De Bordeaux | Bordeaux | France | Associatedpartner |
| Universite De Montpellier | Montpellier | France | Associatedpartner |
| Universite De Strasbourg | Strasbourg | France | Associatedpartner |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| Micromass UK Ltd | Wilmslow Cheshire | United Kingdom | Associatedpartner |
| The University of Manchester | Manchester | United Kingdom | Associatedpartner |
| Agilent Technologies, Inc. | Santa Clara | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI